Retinitis pigmentosa may be treated by reprogramming sugar metabolism

November 14, 2016, Columbia University Medical Center
Image of retina from right eye of a patient with retinitis pigmentosa due to phosphodiesterase deficiency. Intraretinal pigments (pink) are seen in areas of photoreceptor loss. Credit: The Jonas Children's Vision Care, Columbia University Medical Center

Columbia University Medical Center (CUMC) researchers have demonstrated that vision loss associated with a form of retinitis pigmentosa (RP) can be slowed dramatically by reprogramming the metabolism of photoreceptors, or light sensors, in the retina. The study, conducted in mice, represents a novel approach to the treatment of RP, in which the therapy aims to correct downstream metabolic aberrations of the disease rather than the underlying genetic defect.

The findings were published online today in the Journal of Clinical Investigation.

"Although gene therapy has shown promise in RP, it is complicated by the fact that defects in 67 genes have been linked to the disorder, and each would require a different therapy," said study leader Stephen H. Tsang, MD, PhD, the László Z. Bitó Associate Professor of Ophthalmology, Pathology and Cell Biology, and the Institute of Human Nutrition. "Our study shows that precision metabolic reprogramming can improve the survival and function of affected rods and cones in at least one type of RP. Since many, if not most, forms of the disorder have the same metabolic error, precision reprogramming could conceivably be applied to a wide range of RP patients."

RP, an inherited form of , is caused by genetic defects that lead to the breakdown and loss of rods, the photoreceptors in the retina that enable peripheral and night vision. Over time, the deterioration of rods compromises the function of cones, the color-sensing photoreceptors. People with RP start to experience vision loss in childhood, and many are blind by the time they reach adulthood. Currently, there is no cure or effective treatment for RP, which affects about 1 in 4,000 people worldwide.

Rods are among the most metabolically active cells in the body. They are particularly active during periods of darkness, when they burn glucose to release energy. In an earlier paper, Dr. Tsang and his colleagues theorized that rods deteriorate in RP, in part, because they lose the daytime's ability to use glucose to rebuild the rods' outer segment (the light-absorbing portion of the photoreceptor). "We hypothesized that diseased rods could be rescued by reprogramming ," said Dr. Tsang.

Dr. Tsang tested this hypothesis in mice with a mutation in the Pde6 gene that disrupts rod metabolism, leading to an RP-like disorder. The mice were treated so that their rods could not express Sirt6, a gene that inhibits sugar metabolism.

Examination of photoreceptors with electroretinography showed that the mice had significantly greater measures of rod and cone health than untreated controls. Overall, the metabolomes (all of the metabolites found in an organism) of the treated mice had accumulated the molecules needed to build the outer segment. In addition, both rods and cones survived longer in the treated mice than in the controls.

While the treatment significantly prolonged survival of the diseased rods and cones, it did not prevent their eventual death. "Our next challenge is to figure out how to extend the therapeutic effect of Sirt6 inhibition," said Dr. Tsang.

"Although the treatment that was used in the mice cannot be applied directly to humans, several known Sirt6 inhibitors could be evaluated for clinical use," according to Vinit B. Mahajan, MD, PhD, a contributing researcher from the University of Iowa. The inhibitors include enzyme blockers called thiomyristoyl peptides, a common plant pigment known as quercetin, and vitexin, a substance derived from the English Hawthorn tree.

Dr. Tsang noted, "Further studies are needed to explore the exciting possibility that precision metabolic reprogramming may be used to treat other forms of RP and retinal degeneration."

Explore further: Researchers identify treatment target for blinding diseases

More information: "Reprogramming Sirtuin-6 Attenuates Retinal Degeneration" Journal of Clinical Investigation, 2016.

Related Stories

Researchers identify treatment target for blinding diseases

September 28, 2016
New research published in Cell Reports identifies a potential treatment target for blinding diseases such as retinitis pigmentosa and advanced dry age-related macular degeneration. In the study, researchers at Washington ...

Altering eye cells may one day restore vision

January 25, 2013
(Medical Xpress)—Doctors may one day treat some forms of blindness by altering the genetic program of the light-sensing cells of the eye, according to scientists at Washington University School of Medicine in St. Louis.

Gene therapy gives long-term protection to photoreceptor cells

July 15, 2015
A collaboration between scientists in the UK and the USA has shown that gene therapy can give life-long protection to the light-sensitive photoreceptor cells responsible for colour vision in a mouse model of the most common ...

New function for rods in daylight

November 19, 2014
(Medical Xpress)—Vision – so crucial to human health and well-being – depends on job-sharing by just a few cell types, the rod cells and cone cells, in our retina. Botond Roska and his group have identified a novel ...

Newly developed chemical restores light perception to blind mice

February 19, 2014
Progressive degeneration of photoreceptors—the rods and cones of the eyes—causes blinding diseases such as retinitis pigmentosa and age-related macular degeneration. While there are currently no available treatments to ...

Recommended for you

Sleep in your contacts, risk serious eye damage: CDC

August 16, 2018
(HealthDay)—A 59-year-old man was in the shower, wiping his eyes with a towel, when he heard a popping sound and felt pain shoot through his left eye.

Researchers reverse congenital blindness in mice

August 15, 2018
Researchers funded by the National Eye Institute (NEI) have reversed congenital blindness in mice by changing supportive cells in the retina called Müller glia into rod photoreceptors. The findings advance efforts toward ...

Autoimmune response drives vision loss in glaucoma

August 10, 2018
A research team from Massachusetts Eye and Ear and the Massachusetts Institute of Technology has shown that immune cells in the eye that developed in response to early exposure to bacteria are a key contributor to progressive ...

Is too much screen time harming children's vision?

August 6, 2018
As children spend more time tethered to screens, there is increasing concern about potential harm to their visual development. Ophthalmologists—physicians who specialize in medical and surgical eye care—are seeing a marked ...

Researchers chart a course for AI-aided diagnosis of degenerative eye conditions

August 1, 2018
A team of researchers from Johns Hopkins is leading the way in understanding how the advent of electronic medical records with large image databases and advances in artificial intelligence with deep learning can offer medical ...

Derivative of turmeric eye drops could treat glaucoma

July 24, 2018
A derivative of turmeric could be used in eye drops to treat the early stages of glaucoma, finds a new study led by UCL and Imperial College London researchers.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.